Literature DB >> 3294066

Lack of insulinotropic effect of endogenous and exogenous cholecystokinin in man.

J Reimers1, M Nauck, W Creutzfeldt, J Strietzel, R Ebert, P Cantor, G Hoffmann.   

Abstract

Intraduodenal phenylalanine administration (333 mg/min over 60 min) released endogenous cholecystokinin in healthy young subjects as demonstrated radioimmunologically and by intraduodenal bilirubin and pancreatic enzyme output. Concomitantly, there was only a small increase over basal in circulating immunoreactive-insulin and immunoreactive-C-peptide concentrations. In healthy volunteers intraduodenal infusions of saline (10 ml/min), glucose (333 mg/min) or phenylalanine (333 mg/min) were performed for 60 min when plasma glucose was clamped at approximately 8 mmol/l. Phenylalanine enhanced immunoreactive-insulin and immunoreactive-C-peptide responses three-fold more than did the same amount of glucose. Immuno-reactive gastric inhibitory polypeptide responses were small and not different after glucose and phenylalanine administration. Immunoreactive cholecystokinin was significantly stimulated to 9.4 +/- 1.4 pmol/l only by intraduodenal phenylalanine. Plasma phenylalanine concentrations increased into the supraphysiological range (approximately 1.5 mmol/l). Intravenous infusions of phenylalanine achieving plasma concentrations of 1.2 mmol/l stimulated insulin secretion at elevated plasma glucose concentrations (approximately 8 mmol/l clamp experiments), but had no effect at basal plasma glucose concentrations. A small increase in cholecystokinin also was observed. Intravenous infusions of synthetic sulphated cholecystokinin-8 leading to plasma concentrations in the upper postprandial range (8-12 pmol/l) did not augment the immunoreactive-insulin or immunoreactive-C-peptide levels during hyperglycaemic clamp experiments, in the absence or presence of elevated plasma phenylalanine concentrations. It is concluded that the augmentation of the glucose-induced insulin release by intraduodenal administration of phenylalanine cannot be related to cholecystokinin release, but rather is explained by the combined effects of elevated glucose and phenylalanine concentrations. In man, cholecystokinin does not augment insulin secretion caused by moderate hyperglycaemia, elevations of phenylalanine concentrations, or combinations thereof.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3294066     DOI: 10.1007/bf00277407

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  40 in total

Review 1.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

2.  Evaluation of a radioimmunoassay for cholecystokinin in human plasma.

Authors:  P Cantor
Journal:  Scand J Clin Lab Invest       Date:  1986-05       Impact factor: 1.713

3.  Pancreatic alpha- and beta-cell responses to GIP infusion in normal man.

Authors:  D Elahi; D K Andersen; J C Brown; H T Debas; R J Hershcopf; G S Raizes; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-08

4.  Synergistic effect of essential amino acids and glucose upon insulin secretion in man.

Authors:  J C Floyd; S S Fajans; S Pek; C A Thiffault; R F Knopf; J W Conn
Journal:  Diabetes       Date:  1970-02       Impact factor: 9.461

5.  Influence of cholecystokinin on insulin output from isolated perifused pancreatic islets.

Authors:  W S Zawalich; S B Cote; V A Diaz
Journal:  Endocrinology       Date:  1986-08       Impact factor: 4.736

6.  Enhancement of arginine-induced insulin secretion in man by prior administration of glucose.

Authors:  S R Levin; J H Karam; S Hane; G M Grodsky; P H Forsham
Journal:  Diabetes       Date:  1971-03       Impact factor: 9.461

7.  Enhanced glucose utilization during prolonged glucose clamp studies.

Authors:  L Doberne; M S Greenfield; B Schulz; G M Reaven
Journal:  Diabetes       Date:  1981-10       Impact factor: 9.461

8.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

9.  Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans.

Authors:  R J Rushakoff; I D Goldfine; J D Carter; R A Liddle
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

10.  Effects of cholecystokinin (CCK)-4, nonsulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: studies in vitro.

Authors:  K Hermansen
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

View more
  3 in total

1.  Cholecystokinin is not a physiological regulator of gastric pepsin secretion in rats.

Authors:  S Kawabata; S Kanayama; Y Shinomura; S Kondo; Y Matsuzawa
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

2.  GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism.

Authors:  Hua V Lin; Alexander M Efanov; Xiankang Fang; Lisa S Beavers; Xuesong Wang; Jingru Wang; Isabel C Gonzalez Valcarcel; Tianwei Ma
Journal:  PLoS One       Date:  2016-06-20       Impact factor: 3.240

3.  Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets.

Authors:  Arnaldo Henrique de Souza; Jiayin Tang; Amanjot Kaur Yadev; Samuel T Saghafi; Carly R Kibbe; Amelia K Linnemann; Matthew J Merrins; Dawn Belt Davis
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.